As biotechnology companies focus on nanotechnology to treat and diagnose cancer, experts believe the industry may be at a turning point. "We have been hearing about the promise of nanomedicine for a long time, but it is now really starting to move," said Dan Peer, head of a nanomedicine laboratory at Tel Aviv University. "We will see more and more products in clinical testing over the next few years."

Related Summaries